What's the role of topiramate in the management of patients with hyperkinetic movement disorders?

Pharmacol Rep. 2012;64(1):24-30. doi: 10.1016/s1734-1140(12)70727-2.

Abstract

Topiramate (TPM) is an O-alkyl sulfamate derivative of the naturally occurring monosaccharide D-fructose with an epileptic activity. However, it has been suggested that, in addition to its use in epilepsy, TPM could also be used in the treatment of neurological disorders, psychiatric conditions and hyperkinetic movement disorders. The clinical applications of TPM in hyperkinetic movement disorders is consistent with the multiple pharmacodynamic mechanisms e.g., the modulation of both γ-aminobutyric acidergic or glutamatergic neurotransmission and the modulation of voltage-gated ion channels or intracellular signalling pathways. The purpose of the present review is to describe the mechanisms of action of TPM and its clinical efficacy in patients with hyperkinetic movement disorders.

Publication types

  • Review

MeSH terms

  • Animals
  • Fructose / analogs & derivatives*
  • Fructose / pharmacology
  • Fructose / therapeutic use
  • Humans
  • Hyperkinesis / drug therapy*
  • Hyperkinesis / metabolism
  • Movement Disorders / drug therapy*
  • Movement Disorders / metabolism
  • Nervous System Diseases / drug therapy*
  • Nervous System Diseases / metabolism
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Topiramate

Substances

  • Neuroprotective Agents
  • Topiramate
  • Fructose